Navigation Links
New Positive Phase III Study for NER1006 - The First 1 Litre PEG-Based Bowel Preparation

LONDON, May 24, 2016 /PRNewswire/ --


  • Study met both primary endpoints demonstrating non-inferiority in overall bowel cleansing and superiority in 'Excellent plus Good' cleansing of the ascending colon 

     (Logo: )

Norgine B.V. today announced new positive data from the phase III MORA study for NER1006 (1 litre PEG and ascorbate bowel preparation) versus standard 2 litre PEG with ascorbate. The study met both primary endpoints showing that when administered as either a 2-day overnight or 1-day morning split-dosing regimen, and compared to 2L PEG, NER1006 was:

  • Non-inferior in achieving overall bowel cleansing
  • Non-inferior and superior in achieving 'Excellent plus Good' cleansing of the ascending colon

In addition, the study showed that as a 2-day overnight or 1-day morning split-dosing regimen, NER1006 was non-inferior in detecting adenomas and polyps in the ascending and overall colon and as a 2-day overnight split-dosing regimen, it demonstrated a superior polyp detection rate in the ascending colon.

The overall tolerability and safety profile of NER1006 was comparable to that of 2L PEG. Treatment related adverse events were mild or moderate in severity and reflected the expected safety profile of the respective treatments.

The threshold for statistical significance in this study was P<0.025 and a 10% margin was used to demonstrate non-inferiority vs. 2L PEG. [1]

Peter Martin, Norgine's Chief Operating Officer, said: "The new positive phase III MORA results for NER1006 are promising because we know that the quality of a bowel preparation is an important factor for a successful colonoscopy and detecting polyps and tumours. These data reinforce Norgine's leadership in colonoscopy to provide patients with innovative treatments."

NER1006 is not yet approved for use. Norgine intends to submit NER1006 for approval in the US and EU.

The data was presented at Digestive Disease Week on 24 May 2016, 09:30-16:30.

To view the full press release go to


1. Raf Bisschops, Jonathan Manning, Lucy Clayton, Richard Ng Kwet Shing, Marco A. Alvarez-Gonzalez (2016): Efficacy and Safety of the Novel 1L PEG and Ascorbate Bowel Preparation NER1006 Versus Standard 2L PEG With Ascorbate in Overnight or Morning Split-Dosing Administration: Results from the Phase 3 Study MORA. Gastroenterology, Vol. 150, Issue 4, S1269-S1270. Abstract Tu2084. 


Media Contacts:
Isabelle Jouin, T: +44-(0)1895-453643
Charlotte Andrews, T: +44-(0)1895-453607
Follow us @norgine

SOURCE Norgine B.V.
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaMar Reports Positive Results from the Phase I Study of plitidepsin in Combination with bortezomib and dexamethasone in Patients with Multiple Myeloma at the 2016 ASCO Annual Meeting
2. Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study
3. Breast Pumps Outlook Remain Positive, Sleek, Smart to Dominate the Market: Future Market Insights (FMI)
4. Celsion Corporation Announces Positive Data from the First Cohort of Patients in the OVATION Study
5. Oasmia Pharmaceutical Announces Positive Overall Survival Results From Phase III Study of Apealea/Paclical for Treatment of Ovarian Cancer
6. NICE Provides Positive Guidance on electroCores gammaCore Treatment for the Prevention and Acute Treatment of Migraine and Cluster Headache
7. Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome
8. Alexza Pharmaceuticals Receives Positive Nasdaq Listing Determination
9. ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
10. 2016 HIMSS Connected Health Survey Suggests Positive Future for Connected Health Technologies in U.S. Hospitals
11. scPharmaceuticals Announces Positive Results from Pivotal Trial of Second Program - Subcutaneous Ceftriaxone for Treatment of Bacterial Infections
Post Your Comments:
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence ... advanced Parkinson,s, according to a study released today that will ... Annual Meeting in Boston , April ... to the treatment of Parkinson,s disease, the oral drug levodopa ... life and longevity. But as the disease progresses, the effects ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ... HR decision-makers are preparing for how his administration could impact the employee benefits ... into what changes are most likely to make it through Congress. His discussion ...
(Date:4/25/2017)... NV (PRWEB) , ... April 25, 2017 , ... ... now choose a modern procedure that achieves results in a fraction of the ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment ...
(Date:4/25/2017)... Minneapolis MN (PRWEB) , ... April 25, 2017 , ... ... patients and recreational users to dispensaries and head shops –can’t help but be heartened ... loathing for the tell-tale cannabis odor aptly described as “skunk smell.” At last ...
(Date:4/25/2017)... ... 2017 , ... There is no better place in South Florida to undergo ... the May issue of Consumer Reports focused on heart health. , The magazine ... and after coronary bypass and aortic valve replacement procedures. , Consumer Reports rated ...
(Date:4/24/2017)... FLORIDA (PRWEB) , ... April 24, 2017 , ... ... telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, ... LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet ...
Breaking Medicine News(10 mins):